ClinicalTrials.gg
CompletedNCT05613387Updated Jun 18, 2024

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

A Phase 1 interventional study of ZP8396 and Drug: Placebo (ZP8396) in Overweight, Healthy Volunteers and Obese, sponsored by Zealand Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Zealand Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 151 studies in Overweight with a site in Germany — 40 open to participants now, 62 under way, 34 of them phase 3. Overweight · Germany.

Enrollment
106th of 142
68 · median 131
Started
2022
with 3 others
Phase 1
25 of 151
7 open now
Registered
75th of 151
by date
Lead sponsor
6 of 151
Zealand Pharma

Among the 151 studies in Overweight with a site in Germany, this one is the 106th largest by enrollment of the 142 interventional ones that give a count, is one of 4 that started in 2022, is one of 25 in phase 1, and was the 75th registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 856 are open to participants now.

Browse Overweight studies →

Open to participants now

40 of the 151 studies in Overweight with a site in Germany are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 531 Overweight studies recruiting now, 159 (30%) set no upper age limit and 344 (65%) stop at 75 or younger; 63 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Overweight with a site in Germany, or all of them as a file.
02

Study summary

The trial is a single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial in normal weight and overweight but otherwise healthy subjects randomised to subcutaneous administration of ZP8396 or placebo

Read the detailed description

The research study will investigate the safety and tolerability of ZP8396 in healthy study participants. In addition, the study will investigate how ZP8396 works in the body (pharmacokinetics and pharmacodynamics).

The trial is divided in two parts:

Part 1: 20 Participants will receive 6 once-weekly doses as an injection under the skin (subcutaneous, s.c.). Participants will have 14 visits with the study team. 6 of these visits consists of overnight stays of different duration (2-4 nights) at the study site. For each participant, the study will last up to 116 days.

Part 2: 48 Participants will receive 16 once-weekly doses as an injection under the skin (subcutaneous, s.c.) in a dose up-titration dose scheme. Participants will have 23 or 24 visits with the study team. 13 of these visits consists of overnight stays of different duration (2-4 nights) at the study site. For each participant, the study will last up to 198 days.

03

Conditions studied

  • Overweight
  • Healthy Volunteers
  • Obese
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  • (BMI) between 21.0 and 29.9 kg/m\^2, both inclusive
  • Glycosylated () below 5.7 percent

Further inclusion criteria apply

Part 2:

  • Body Mass Index (BMI) between 27.0 and 39.9 kg/m\^2, both inclusive
  • Glycosylated hemoglobin (HbA1c) below 6.5 percent

Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

Part 1:

  • History of metabolic diseases more frequently associated with obesity, e.g. type-2-diabetes mellitus, hypertension, dyslipidemia, heart disease or stroke
  • Systolic blood pressure below 90 mmHg or above 139 mmHg and/or diastolic blood pressure below 50 mmHg or above 89 mmHg
  • Symptoms of arterial hypotension

Further exclusion criteria apply

Part 2:

  • History of metabolic diseases more frequently associated with obesity, e.g. type-2-diabetes mellitus, hypertension, dyslipidemia, heart disease or stroke
  • Systolic blood pressure below 90 mmHg or above 159 mmHg and/or diastolic blood pressure below 50 mmHg or above 99 mmHg
  • Symptoms of arterial hypotension

Further exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    ZP8396

    Part 1: 2 dose cohorts are planned with 10 subjects in each; 7 participants in each cohort will receive active treatment. Part 2: 3 dose cohorts are planned with 16 subjects in each; 12 participants in each cohort will receive active treatment.

    Drug: ZP8396

  • Placebo comparator
    Placebo (ZP8396)

    Part 1: In each of the 2 dose cohorts, 3 subjects will receive placebo. Part 2: In each of the 3 cohorts, 4 subjects will receive placebo.

    Drug: Drug: Placebo (ZP8396)

Interventions

  • DrugZP8396

    Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used.

  • DrugDrug: Placebo (ZP8396)

    Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin). Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin).

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Incidence of TEAEs from 1st dosing day to end of trial

    Time frame: Part 1: From dosing (Day 1) to end of trial (Day 92); Part 2: From dosing (Day 1) to end of trial (Day 169 for Cohort 1 and 2, Day 176 for Cohort 3)

Secondary outcomes

  1. Pharmacokinetics (PK) of ZP8396 (AUCτ)

    Area under the plasma concentration-time curve over a dosing interval. Samples will be taken at set time points throughout the trial.

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  2. Pharmacokinetics (PK) of ZP8396 (AUCinf)

    Area under the plasma concentration-time curve from time zero to infinity. Samples will be taken at set time points throughout the trial.

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  3. Pharmacokinetics (PK) of ZP8396 (AUClast)

    Area under the plasma concentration-time curve from time zero to the time of the last measurable concentration. Samples will be taken at set time points throughout the trial.

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  4. Pharmacokinetics (PK) of ZP8396 (Cmax)

    Maximum (peak) plasma drug concentration

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  5. Pharmacokinetics (PK) of ZP8396 (tmax)

    Time to reach maximum (peak) plasma concentration

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  6. Pharmacokinetics (PK) of ZP8396 (λz)

    Elimination rate constant

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  7. Pharmacokinetics (PK) of ZP8396 (t½)

    Elimination half-life

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  8. Pharmacokinetics (PK) of ZP8396 (Vz/f)

    Apparent volume of distribution

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  9. Pharmacokinetics (PK) of ZP8396 (CL/f)

    Apparent total clearance of the drug from plasma

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  10. Pharmacokinetics (PK) of ZP8396 (Ctrough)

    Trough concentration measured pre-dose

    Time frame: Part 1: Day 1 (pre-dose) to Day 92; Part 2: Day 1 (pre-dose) to Day 169 for Cohort 1 and 2, Day 176 for Cohort 3

  11. Accumulation Ratio for AUCτ

    Accumulation Ratio for AUCτ

    Time frame: Part 1: Day 1 (pre-dose) to Day 92

  12. Accumulation Ratio for Cmax

    Accumulation Ratio for Cmax

    Time frame: Part 1: Day 1 (pre-dose) to Day 92

  13. Pharmacodynamics (PD) of ZP8396 (Cmax acetaminophen)

    Maximum acetaminophen concentration after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  14. Pharmacodynamics (PD) of ZP8396 (Tmax acetaminophen)

    Time to maximum acetaminophen concentration after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  15. Pharmacodynamics (PD) of ZP8396 (AUCacetaminophen, 0-60 min)

    Area under the acetaminophen concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  16. Pharmacodynamics (PD) of ZP8396 (AUCacetaminophen, 0-240 min)

    Area under the acetaminophen concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  17. Pharmacodynamics (PD) of ZP8396 (Emax, Plasma Glucose [PG])

    Maximum PG concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  18. Pharmacodynamics (PD) of ZP8396 (Tmax, Plasma Glucose [PG])

    Time to maximum PG concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  19. Pharmacodynamics (PD) of ZP8396 (AUE, Plasma Glucose [PG], 0-60 minutes)

    Area under the acetaminophen concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  20. Pharmacodynamics (PD) of ZP8396 (AUE, Plasma Glucose [PG], 0-240 minutes)

    Area under the acetaminophen concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40; Part 2: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1, Day 110 for cohort 1 and 2, Day -1, Day 1, Day 107 for cohort 3

  21. Pharmacodynamics (PD) of ZP8396 (Emax, insulin)

    Maximum insulin concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  22. Pharmacodynamics (PD) of ZP8396 (Tmax, insulin)

    Time to maximum insulin concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  23. Pharmacodynamics (PD) of ZP8396 (AUEinsulin,0-60 minutes)

    Area under the insulin concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  24. Pharmacodynamics (PD) of ZP8396 (AUEinsulin,0-240 min)

    Area under the insulin concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  25. Pharmacodynamics (PD) of ZP8396 (Emax, glucagon)

    Maximum glucagon concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  26. Pharmacodynamics (PD) of ZP8396 (Tmax, glucagon)

    Time to maximum glucagon concentration from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  27. Pharmacodynamics (PD) of ZP8396 (AUEglucagon,0-60 minutes)

    Area under the glucagon concentration-time curve from 0 to 60 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-60 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

  28. Pharmacodynamics (PD) of ZP8396 (AUEglucagon,0-240 minutes)

    Area under the glucagon concentration-time curve from 0 to 240 minutes after ingestion of a standardised Mixed Test Meal (MTM) and 1000 mg acetaminophen

    Time frame: Part 1: 0-240 minutes, relative to ingestion of MTM/acetaminophen on Day -1 (baseline), Day 5 and Day 40

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, North Rhine-Westphalia 41460, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Jun 2024, 19 months.

Of 211 industry-sponsored phase 1 interventional studies under Overweight, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 19 months is above that.

Counting every sponsor, half of 230 studies reached it within 9 months; a quarter within 5 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2022
First posted
Nov 14, 2022
StartActual
Nov 7, 2022
Primary completionActual
Jun 13, 2024
CompletionActual
Jun 13, 2024
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05613387
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Nov 7, 2022
Primary completion
Jun 13, 2024
Completion
Jun 13, 2024
Last update
Jun 18, 2024

Study contacts

Zealand Pharma A/S
study director · Zealand Pharma A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Petrelintide

Start the discussion